Ensign Peak Advisors, Inc Keros Therapeutics, Inc. Transaction History
Ensign Peak Advisors, Inc
- $56.1 Billion
- Q3 2024
A detailed history of Ensign Peak Advisors, Inc transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 71,740 shares of KROS stock, worth $817,836. This represents 0.01% of its overall portfolio holdings.
Number of Shares
71,740
Previous 71,740
-0.0%
Holding current value
$817,836
Previous $3.28 Million
27.06%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding KROS
# of Institutions
175Shares Held
30MCall Options Held
76.8KPut Options Held
9K-
Black Rock Inc. New York, NY2.51MShares$28.7 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.9MShares$21.6 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.86MShares$21.2 Million0.0% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.52MShares$17.4 Million7.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.51MShares$17.3 Million0.01% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $294M
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...